Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402997 | 0.83 | HRH3 (0.37) | HRH3BCHEJAK2JAK1HRH2 | |
| SCHEMBL5663352 | 0.82 | HRH3 (0.46) | HRH3BCHEJAK2JAK1HRH2 | |
| SCHEMBL12841915 | 0.82 | MEN1 (0.41) | KMT2A | |
| SCHEMBL8441895 | 0.77 | SMN1; SMN2 (0.35) | HRH3KMT2A | |
| SCHEMBL13456547 | 0.74 | KMT2A (0.35) | KMT2A | |
| SCHEMBL3939592 | 0.74 | ADH1C (0.32) | KMT2A | |
| SCHEMBL2116542 | 0.73 | GNAO1 (0.36) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL26498841 | 0.73 | GNAO1 (0.55) | BCHEKMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL2115304 | 0.72 | SIGMAR1 (0.41) | HRH3KMT2A | |
| SCHEMBL2116364 | 0.71 | BCHE (0.33) | HRH3BCHEGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HRH3 673/4885BCHE 3544/4885JAK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.